Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
1585(c) 1599(c) 1566(c) 1558.5(c) 1550 Last
8 430 506 8 665 852 17 383 205 10 031 036 10 615 813 Volume
+1.25% +0.88% -2.06% -0.48% -0.55% Change
More quotes
Financials ( GBP)
Sales 2017 30 016 M
EBIT 2017 8 355 M
Net income 2017 4 191 M
Debt 2017 14 113 M
Yield 2017 5,14%
Sales 2018 31 086 M
EBIT 2018 8 768 M
Net income 2018 4 813 M
Debt 2018 13 436 M
Yield 2018 5,18%
P/E ratio 2017 18,77
P/E ratio 2018 16,18
EV / Sales2017 3,02x
EV / Sales2018 2,90x
Capitalization 76 636 M
More Financials
Company
GlaxoSmithKline Plc operates as a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands.It operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare.The Pharmaceuticals business researches, develops... 
Sector
Pharmaceuticals
Calendar
07/26Earnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline plc
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE PLC
09:36p GLAXOSMITHKLINE : Uni in Pounds 7.9m boost
07:23p GLAXOSMITHKLINE : Blockbuster drugs will lead sales bonanza at pounds sterling 8..
04:00p GLAXOSMITHKLINE : GSK Consumer Healthcare South Asia Head calls on Health Minist..
04/27 GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Describe New Findings in Immu..
04/27 GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Describe Findings in Mult..
04/27 GLAXOSMITHKLINE : Report Summarizes Asthma Study Findings from GlaxoSmithKline p..
04/27 GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Describe New Findings in Mono..
04/27 GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Report Findings in Clinic..
04/27DJGLAXOSMITHKLINE : New Glaxo CEO Seeks Tighter Drug Focus -- WSJ
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
More news
Sector news : Pharmaceuticals - NEC
05:59pDJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
02:37pDJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
10:30a REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on GLAXOSMITHKLINE PLC 
2015This could be the time to buy
2014Bearish signal below GBp 1415
More Strategies
Latest Tweets
07:29pDuncker Streett & Co. Inc. Has $122,000 Position in GlaxoSmithKline plc $.. 
06:14pGlaxoSmithKline plc $GSK Position Decreased by Independent Portfolio Consulta.. 
04:09pInnoviva Reports First Quarter 2017 Financial Results  
04/27Innoviva misses by $0.07, misses on revenue  
04/27Innoviva Reports First Quarter 2017 Financial Results  
More tweets
Qtime:214
News from SeekingAlpha
04/27 GLAXOSMITHKLINE Q1 2017 : Mixed Signals For Investors
04/26 GLAXOSMITHKLINE : Good News, 2016's Positive Momentum Continues
04/26 GlaxoSmithKline Plc (GSK) Q1 2017 Results - Earnings Call Transcript
04/26 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2017 Update
04/26 GlaxoSmithKline Q1 revenues up 19%; non-GAAP EPS up 32%
Advertisement
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,8  GBP
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-0.22%98 898
JOHNSON & JOHNSON7.40%335 446
ROCHE HOLDING LTD.10.83%225 921
NOVARTIS AG2.77%203 449
PFIZER INC.4.25%201 641
MERCK & CO., INC.6.30%171 565
More Results